Natural History of Duchenne Muscular Dystrophy Cardiomyopathy (DMD-CMP)

Prospective Cardiac Magnetic Resonance Imaging Study in Duchenne Muscular Dystrophy (DMD-CMP)

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05558813

Acronym

DMD-CMP

Enrollment

Registered

2022-09-28

Start date

2024-11-30

Completion date

2029-04-30

Last updated

2025-11-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne Muscular Dystrophy

Keywords

Duchenne, dystrophin, cardiomyopathy, cardiac MRI

Brief summary

The purpose of this study is to describe the progression of tissular and functional myocardial abnormalities in patients with Duchenne muscular dystrophy using cardiac magnetic resonance imaging and blood biomarkers assays.

Detailed description

This study is to describe the progression of tissular (late gadolinium enhancement, T1, T2, ECV assessments) and functional (segmental and global contractility, strain) myocardial abnormalities in patients with Duchenne muscular dystrophy using cardiac magnetic resonance imaging and blood biomarkers assays (troponin I, NTproBNP). Comparison between baseline and 2-years assessments will be conducted.

Interventions

DIAGNOSTIC_TESTCardiac MRI

two cardiac MRIs with Gadolinum injection at 2-year intervals

BIOLOGICALBlood assays

blood samples for the determination of blood biomarkers of heart failure (BNP, NTproBNP) and for the constitution of a biological collection

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

6 Years to No maximum

Healthy volunteers

Inclusion criteria

: * Age \>= 6 years * Genetically proven Duchenne muscular dystrophy * Affiliation to French medical insurance * Informed consent provided

Exclusion criteria

: * Age \<6 years * Left ventricular ejection fraction \<30% * Tracheostomy of hospitalisation for acute respiratory failure \<1 year * Contraindication to MRI: claustrophobia, Gadolinum allergy

Design outcomes

Primary

Measure	Time frame
Late gadolinium enhancement burden on cardiac MRI	2 years

Secondary

Measure	Time frame
Global T2 on cardiac MRI	2 years
Global extracellular volume on cardiac MRI	2 years
Left ventricular ejection fraction on cardiac MRI	2 years
Left ventricular systolic circumferentiel strain ejection fraction on cardiac MRI	2 years
Global T1 on cardiac MRI	2 years
Left ventricular systolic longitudinal strain on cardiac MRI	2 years
NTproBNP assay in the blood	2 years
Troponin I assay in the blood	2 years
Left ventricular systolic radial strain ejection fraction on cardiac MRI	2 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026